20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
- Immunome Inc (NASDAQ:IMNM) has announced that its three-antibody cocktail (IMM-BCP-01) has demonstrated potent neutralizing activity against COVI-19 Delta variant in pre-clinical pseudovirus testing.
- Furthermore, IMM-BCP-01 showed in-vitro activity via non-neutralizing mechanisms, such as complement fixation, which Immunome expects will enable viral clearance.
- Immunome was awarded a $17.6 million technology award from the U.S. Department of Defense's Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense, collaborating with the Defense Health Agency to support the COVID program.
- The Company plans to submit an IND application with the FDA in 3Q of 2021.
- Price Action: IMNM shares are up 32.70% at $22.05 during the premarket session on the last check Tuesday.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!